Table 4.
Univariate and multivariate analysis of various factors between ES and Non ES
| Engraftment syndrome yes/no (n = 46/132) | P value univariate/multivariate | ||
|---|---|---|---|
| Sex | |||
| Female | 20 (37%) | 34 (63%) | 0.065/0.073 |
| Male | 26 (22.2%) | 91 (77.8%) | |
| Diagnosis | |||
| Multiple myeloma | 23 (26.4%) | 64 (73.6%) | 0.361 |
| Non-Hodgkins lymphoma | 7 (20.6%) | 27 (79.4%) | |
| Hodgkins lymphoma | 16 (33%) | 32 (67%) | |
| Others | 0 | 2 | |
| Disease status | |||
| Early | 18 (27.3%) | 48 (72.7%) | 0.924/0.992 |
| Advanced | 25 (34%) | 76 (66%) | |
| Number of chemotherapy regimens (median = 2) | |||
| ≤ 2 | 34 (26%) | 94 (74%) | 0.552/0.674 |
| > 2 | 9 (34.6%) | 17 (63.4%) | |
| No of chemotherapy cycles (median = 9) | |||
| ≤ 9 | 28 (29.2%) | 68 (70.8%) | 0.714 |
| > 9 | 14 (25%) | 42 (75%) | |
| Total CD34 dose (median 3.3) | |||
| ≤ 3.3 | 20 (32.3%) | 42 (67.7%) | 0.720/0.118 |
| > 3.3 | 16 (26.7%) | 42 (72.4%) | |
| CD34 > 2 on day 1 | |||
| Yes | 11 (25%) | 33 (75%) | 0.423 |
| No | 26 (33.8%) | 51 (66.2%) | |
| Mobilization | |||
| Filgrastim | 17 (21%) | 64 (79%) | 0.138/0.722 |
| Pegfilgrastim | 29 (32.2%) | 61 (67.8%) | |
| Conditioning | |||
| Melphalan | 23 (26.4%) | 64 (73.6%) | 0.176 |
| LACE | 15 (36.6%) | 26 (73.4%) | |
| BEAM | 6 (20%)/24 (80%) | 24 (80%) | |
| BeEAM | 1 (50%) | 1 (50%) | |
| CBV | 1 (16.7%) | 5 (83.5%) | |
| BACE | 0 | 2 | |
| Others | 0 | 3 | |
| Day of WBC engraftment(median = 11) | |||
| ≤ 11 | 22 (22.7%) | 75 (77.3%) | 0.211/0.446 |
| > 11 | 24 (32.4%) | 50 (67.6%) | |
| Supportive therapy and outcome of patients | |||
| Duration (days) of antibiotic therapy, median (interquartile range-IQR) | 12 (7)/10 (7) | 0.011 | |
| Duration (days) of hospitalization, median (IQR) | 20.5 (6)/17 (8.0) | 0.028 | |
| No. of red blood cell units transfused, median (IQR) | 2 (4)/2 (4) | 0.917 | |
| No. of platelet units transfused, median (IQR) | 4 (5)/3 (4) | 0.184 | |